Antitumor Activity and Mechanism of Action of Hormonotoxin, an LHRH Analog Conjugated to Dermaseptin-B2, a Multifunctional Antimicrobial Peptide

Prostate cancer is the most common cancer in men. For patients with advanced or metastatic prostate cancer, available treatments can slow down its progression but cannot cure it. The development of innovative drugs resulting from the exploration of biodiversity could open new therapeutic alternatives. Dermaseptin-B2, a natural multifunctional antimicrobial peptide isolated from Amazonian frog skin, has been reported to possess antitumor activity. To improve its pharmacological properties and to decrease its peripheral toxicity and lethality we developed a hormonotoxin molecule composed of dermaseptin-B2 combined with d-Lys6-LHRH to target the LHRH receptor. This hormonotoxin has a significant antiproliferative effect on the PC3 tumor cell line, with an IC50 value close to that of dermaseptin-B2. Its antitumor activity has been confirmed in vivo in a xenograft mouse model with PC3 tumors and appears to be better tolerated than dermaseptin-B2. Biophysical experiments showed that the addition of LHRH to dermaseptin-B2 did not alter its secondary structure or biological activity. The combination of different experimental approaches indicated that this hormonotoxin induces cell death by an apoptotic mechanism instead of necrosis, as observed for dermaseptin-B2. These results could explain the lower toxicity observed for this hormonotoxin compared to dermaseptin-B2 and may represent a promising targeting approach for cancer therapy.

[1]  R. McDermott,et al.  Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer , 2021, Diagnostics.

[2]  Xinping Xi,et al.  Novel Frog Skin-Derived Peptide Dermaseptin-PP for Lung Cancer Treatment: In vitro/vivo Evaluation and Anti-tumor Mechanisms Study , 2020, Frontiers in Chemistry.

[3]  F. Buonaguro,et al.  Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities , 2020, Molecules.

[4]  M. Amiche,et al.  Dermaseptins, Multifunctional Antimicrobial Peptides: A Review of Their Pharmacology, Effectivity, Mechanism of Action, and Possible Future Directions , 2019, Front. Pharmacol..

[5]  J. F. Burrows,et al.  A Novel Dermaseptin Isolated from the Skin Secretion of Phyllomedusa tarsius and Its Cationicity-Enhanced Analogue Exhibiting Effective Antimicrobial and Anti-Proliferative Activities , 2019, Biomolecules.

[6]  Prashanth Rawla,et al.  Epidemiology of Prostate Cancer , 2019, World journal of oncology.

[7]  S. Groshen,et al.  A Phase II Trial of AEZS‐108 in Castration‐ and Taxane‐Resistant Prostate Cancer , 2017, Clinical genitourinary cancer.

[8]  M. Amiche,et al.  Studies of the antitumor mechanism of action of dermaseptin B2, a multifunctional cationic antimicrobial peptide, reveal a partial implication of cell surface glycosaminoglycans , 2017, PloS one.

[9]  Zuyue Sun,et al.  A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer , 2016, Scientific Reports.

[10]  M. Borad,et al.  Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[11]  G. Carpentier,et al.  Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2 , 2012, PloS one.

[12]  A. Schally,et al.  Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH) , 2012, Archives of Gynecology and Obstetrics.

[13]  Robert E. W. Hancock,et al.  Multifunctional cationic host defence peptides and their clinical applications , 2011, Cellular and Molecular Life Sciences.

[14]  C. Datz,et al.  Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. , 2010, Cancer letters.

[15]  A. Schally,et al.  Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition , 2009, Anti-cancer drugs.

[16]  O. Lequin,et al.  Mechanism of antibacterial action of dermaseptin B2: interplay between helix-hinge-helix structure and membrane curvature strain. , 2009, Biochemistry.

[17]  Pierre Nicolas,et al.  A consistent nomenclature of antimicrobial peptides isolated from frogs of the subfamily Phyllomedusinae , 2008, Peptides.

[18]  D. Hoskin,et al.  Studies on anticancer activities of antimicrobial peptides. , 2008, Biochimica et biophysica acta.

[19]  C. Aisenbrey,et al.  Macromolecular crowding at membrane interfaces: adsorption and alignment of membrane peptides. , 2008, Journal of molecular biology.

[20]  A. Schally,et al.  Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[21]  B. Bechinger,et al.  Detergent-like actions of linear amphipathic cationic antimicrobial peptides. , 2006, Biochimica et biophysica acta.

[22]  Ira Pastan,et al.  Immunotoxin therapy of cancer , 2006, Nature Reviews Cancer.

[23]  A. Schally,et al.  Minireview. Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers1 , 2005, Biology of reproduction.

[24]  C. Leuschner,et al.  Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors , 2003, The Prostate.

[25]  H. Duclohier.  How do channel- and pore-forming helical peptides interact with lipid membranes and how does this account for their antimicrobial activity? , 2002, Mini reviews in medicinal chemistry.

[26]  G. Emons,et al.  Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. , 2002, American journal of obstetrics and gynecology.

[27]  A. Schally,et al.  Peptide analogs in the therapy of prostate cancer , 2000, The Prostate.

[28]  D. Bostwick,et al.  High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. , 2000, The Journal of urology.

[29]  A. Schally,et al.  Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. , 1999, European journal of endocrinology.

[30]  J. L. Le Caer,et al.  Structure, Synthesis, and Molecular Cloning of Dermaseptins B, a Family of Skin Peptide Antibiotics* , 1998, The Journal of Biological Chemistry.

[31]  W. Grizzle,et al.  The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary , 1994, Molecular and Cellular Endocrinology.

[32]  Y. Shai,et al.  Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. , 1992, Biochemistry.

[33]  W. C. Johnson,et al.  Environment affects amino acid preference for secondary structure. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Böhm,et al.  Quantitative analysis of protein far UV circular dichroism spectra by neural networks. , 1992, Protein engineering.

[35]  A. Schally,et al.  Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. , 2011, Current drug delivery.

[36]  R. Aneja,et al.  LHRH-conjugated lytic peptides directly target prostate cancer cells. , 2011, Biochemical pharmacology.

[37]  A. Ladram,et al.  Antitumor and angiostatic peptides from frog skin secretions , 2010, Amino Acids.

[38]  Y. Shai,et al.  Mode of action of membrane active antimicrobial peptides. , 2002, Biopolymers.